Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Veracyte, Inc.
VCYT
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $4.8B
$57.03
▼ -4.72%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$22.61 - $60.91
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 117.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary genomic sequencing and machine learning algorithms with clinical validation
- Broad multi-cancer portfolio reducing customer switching and increasing wallet share
- Strategic partnerships with Johnson & Johnson and other major healthcare companies
- Strong intellectual property portfolio protecting core diagnostic technologies
Bear Case
2 risks
- Above-average volatility (beta 2.0).
- Significant premium - growth priced in
Growth
Stable outlook
Increasing adoption of precision medicine and genomic testing in oncology
Value
Significant premium - growth priced in
Momentum
Hot
+85.6% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying VCYT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 5, 2026
Reported EPS of $0.52 vs $0.34 consensus (+52.9% surprise). Revenue of $139.1M vs $130.4M expected (+6.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+52.9%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
+21%
+18%
+14%
+14%
+19%
+21%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$114.4M
$115.9M
$118.6M
$114.5M
$130.2M
$131.9M
$140.6M
$139.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
20.6%
Wall Street consensus
5 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
20%
Sell
20%
Median Price Target
$54.50
▼ -4.4% vs $57.03
Latest: Guggenheim · $65.00 · Jun 29, 2026
4 analysts covering